Australia is gain access to innovative medication for obesity: Retatrutide. The dual agonist – working on both GLP-1 and GIP receptors – shows significant outcomes in global research, indicating substantial reductions in BMI. While availability is pending with Australian regulators, many Australians dealing with being overweight could viewing R